A health worker conducts a rapid antibody test for Covid-19 in Vijaywada | Representational image | PTI
A health worker conducts a rapid antibody test for Covid-19 in Vijaywada | Representational image | PTI
Text Size:

New Delhi: Manufacturers of Chinese antibody testing kits for Covid-19 have said they are willing to cooperate in any investigation by the Indian Council of Medical Research (ICMR) into allegations of “malfunctioning”.

In press statements issued late Thursday, Guangzhou Wondfo Biotech Co Ltd and Zhuhai Livzon Diagnostics Inc, the two Chinese companies that have supplied the kits to India, also stated that users need to strictly follow the guidelines on “storage and stability”.

The clarification came days after India, Tuesday, briefly halted the use of antibody tests — a quick diagnostic tool that doesn’t require a laboratory and is being seen as key to easing lockdown restrictions — amid complaints of discrepant results. India is currently using rapid antibody tests from China, South Korea, Germany and France, alongside those from domestic manufacturers.

Expressing “shock” over reports of the rapid test kits malfunctioning, Livzon Diagnostics said, “We have shown great concern on this issue, and we are willing to coordinate with the related Indian government departments for investigation.”

The company added that the ICMR had placed orders with them after it was assured of their quality, saying the results yielded by the kits were also given a thumbs-up by the National Institute of Virology (NIV).

Wondo Biotech said it would “fully cooperate with the ICMR review and re-testing arrangements”. “Safety and product quality are our highest priorities,” it added.

The two companies, which are certified by the Chinese regulator National Medical Products Administration (NMPA), also stressed the need to follow the user manual when using the kits. 

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.

SUBSCRIBE NOW

On 16 April, India received a total of 5.5 lakh rapid antibody testing kits from the Chinese companies — 3 lakh from Wondfo and 2.5 lakh from Livzon.  

Two days later, on 18 April, a second batch of 3 lakh kits came in from China. All the kits were then distributed among the states. 

The two firms noted that negative results from a rapid antibody test “do not rule out” infection, particularly for those who have been in contact with the virus, saying a conclusive diagnosis required follow-up antibody tests along with molecular testing.

Both companies noted that they had supplied testing kits to more than 70 countries and regions in Europe, Asia and Latin America, adding that certain authorised institutions in the US, Denmark and Sweden had evaluated the kits and come up with “excellent results”.

However, there have been reports from different countries, including the UK, about the failure of rapid diagnostic tests


Also Read: India plans to resume trade dialogue with China once Covid situation stabilises: Envoy Misri


India to source more medical devices from China

The procurement of the testing kits was facilitated by the Indian Embassy in Beijing. The government plans to source more medical devices from China in the coming days, Indian Ambassador to China Vikram Misri had told ThePrint in an interview earlier this week.  

“We are in touch with Chinese authorities regarding the procurement of the much needed medical equipment and products by our healthcare fraternity in India,” Misri had said. 

“China happens to be the one of the largest producers of a number of these products.” 

Over the past two weeks, around two dozen flights have departed for India from five cities in China carrying nearly 400 tonnes of medical supplies, including RT-PCR test kits, rapid antibody tests, PPE kits and thermometers among others.

“Around 20 more flights are expected to bring supplies from China in the coming days, and this is likely to be stepped up considerably in the next few months as our procurement efforts gain momentum,” Ministry of External Affairs spokesperson Anurag Srivastava had said Thursday.  

Chinese Ambassador to India Sun Weidong tweeted Friday that China would “continue to support India fighting against Covid-19”.


Also Read: ‘Experimental’ drug that failed to cure ebola is now world’s best shot against COVID-19


 

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

Share Your Views

LEAVE A REPLY

Please enter your comment!
Please enter your name here